news.cision.comnews.cision.com

US/UK/Canada US/UK/Canada Sweden Denmark Finland Germany France Netherlands Norway Portugal Global Login Get a newsroom About Cision Contact Follow us: News Home Get a newsroom About Cision Contact Change Country Sverige Danmark Suomi Deutschland France Netherlands Norge Portugal Global Follow us: Subscribe: All Press releases News Financial reports Media Pick a time period - Search Filter options ( Active) View popular View Newsrooms All Regulatory Non-Regulatory Subscribe: No more available filters You need to apply a filter before selecting newsroom Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with . Subscribe Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing Wed, May 15, 2024 01:30 CET Stockholm, Sweden, May 15, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. In the US, Leqembi is indicated for the treatment of Alzheimer’s disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as Africa Energy Announces Corporate Update and First Quarter 2024 Results Tue, May 14, 2024 23:30 CET VANCOUVER, BC, May 14, 2024 /CNW/ – Africa Energy Corp. (TSX Venture: AFE) (Nasdaq First North: AEC) (Africa Energy” or the Company”), an oil and gas exploration company, announces corporate update and financial and operating results for the three months ended March 31, 2024. FINANCIAL AND OPERATIONAL UPDATE The Company’s financial results for the three months ended March 31, 2024, have been negatively impacted by a US$23.1 million non-cash loss on revaluation of our investment in Block 11B/12B, which was due to changes in base assumptions for discount rates applied in the Communiqué from the Annual General Meeting of Micro Systemation AB (publ) Tue, May 14, 2024 20:30 CET At the Annual General Meeting of Micro Systemation AB (publ) (MSAB”) on 14 May 2024, the following decisions were made. Income statements and balance sheets The Annual General Meeting adopted the income statement and the balance sheet and the consolidated income statement and the consolidated balance sheet for the financial year 2023. Dividend The Annual General Meeting resolved, in accordance with the Board of Directors’ proposal, on an ordinary dividend of SEK 1.50 per share, to be paid through two partial payments. A first payment of SEK 1.00 per share with the record Year-end Report April 2023 – March 2024 Tue, May 14, 2024 20:15 CET Good growth and record amount of launches January - March 2024 · Consolidated sales during the fourth quarter, January to March amounted to SEK 78.1 (60.3) million, an increase of 30%. Adjusted for non-recurring sales in the comparative quarter Q4 2022/23, the revenue amounted to 78.1 (53.5) MSEK, an increase of 46%. · Gross profit amounted to SEK 31.5 (28.1) million for the quarter, an increase of 11%. · EBIT amounted to SEK 8.4 (6.1) million, an increase of 38%. The operating margin was 11% (10%). · EBITDA margin was 14%. · Costs related to preparations for uplisting to Getinge’s financial target 2024-2028: Adjusted EPS growth of above 12% on average Tue, May 14, 2024 20:15 CET Getinge updates its financial target for adjusted EPS growth 2024-2028 to be above 12% on average. The target takes into account today’s decisions (see below) that follow from the letter that the U.S. Food and Drug Administration (FDA) sent to healthcare providers in the US on May 8th. In the letter from the U.S. FDA, there are no new field actions referred to, but healthcare providers are advised to transition from Getinge’s Cardiosave Intra-Aortic Balloon Pump (IABP), Cardiohelp System, and HLS Sets Advanced to alternative products, and to continue using Getinge’s products only if no other Financial Report 1st quarter for DOF Group ASA Tue, May 14, 2024 20:00 CET The reporting currency has been changed from NOK to USD from 1st of January 2024. The Group’s revenue for 1st quarter (management reporting) totals USD 330 million (USD 295 million) and EBITDA totals USD 114 million (USD 104 million). The operating profit (EBIT) is USD 70 million (USD 69 million). Net financial costs amount to USD -52 million (USD -44 million) including unrealised currency loss of USD -26 million (USD -6 million). The result after taxes is USD 6 million (USD -1 million). The Group’s net interest-bearing debt is USD 1,358 million (USD 1,466 million). The equity is USD 1, Wyld Networks AB changes date for publication of annual report Tue, May 14, 2024 19:29 CET The board of directors of Wyld Networks AB (the ”Company”) has resolved to postpone the publication of the annual report for 2023 due to administrative and practical reasons. The new date for publication of the annual report for 2023 is 28 May 2024. An updated financial calendar is available on the Company’s website, www. wyldnetworks.com. For further information about Wyld Networks, please contact: Alastair Williamson, CEO Wyld Networks E-mail: alastair.williamson@wyldnetworks.com Tel: +44 7 824 997 689 About Wyld Networks Wyld Networks develop and sells Bulletin from Balco Group’s Annual General Meeting 2024 Tue, May 14, 2024 19:00 CET The Annual General Meeting of Balco Group AB (publ), (the Company”), was held today on Tuesday May 14, 2024, at Kök 11, Honnörsgatan 15 in Växjö. The Annual General Meeting resolved in accordance with all proposals of the Board of Directors and the Nomination Committee. Dividend The Annual General Meeting resolved to not pay any dividend and that funds at the disposal of the Annual General Meeting are carried forward. The Board of Directors and the auditor The Annual General Meeting resolved on re-election of the Board members Mikael Andersson, Ingalill Berglund, Vibecke Resolutions at GARO Aktiebolag’s Annual General Meeting 2024 Tue, May 14, 2024 19:00 CET The Annual General Meeting approved the presented income statements and balance sheets and remuneration report and approved discharge from liability for board members and the managing director. In addition, the following decisions were made. Election of Board of Directors As board members Rickard Blomqvist (Chairperson), Martin Althén, Susanna Hilleskog, Mari-Katharina Jonsson Kadowaki, Johan Paulsson and Lars Kongstad were re-elected. Fees to the Board of Directors It was resolved that Board fees shall be unchanged and paid by SEK 725,000 to the Chairperson of the Board and SEK 300, Bulletin from the Annual general meeting may 14, 2024 Tue, May 14, 2024 18:57 CET HANZA AB (publ), listed on Nasdaq Stockholm, held its Annual General Meeting today, May 14, 2024, at which, among others, the resolutions listed below were made. · At the Annual General Meeting, the parent company’s and the group’s income statement and balance sheet for the financial year of 2023 were adopted. Further, the General Meeting resolved on allocation of the company’s profit in accordance with the Board’s proposal, entailing that a dividend in the amount of SEK 1,20 per share, in total SEK 52 391 208 be paid. The record date for the dividend shall be Thursday May 16, 2024. The Aker Solutions ASA: Transactions made under the buy-back programme Tue, May 14, 2024 18:49 CET May 14, 2024 – On February 12, 2024, Aker Solutions ASA (Aker Solutions”) announced a share buy-back program of up to NOK 500 million, with a maximum of 12.5 million shares, in the period from 12 February 2024 to 31 July 2024. DNB,...